Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Limertinib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Innovent Biologics
Deal Size : Inapplicable
Deal Type : Inapplicable
Innovent and ASK Pharm Announce NMPA Approval of Limertinib for Lung Cancer
Details : ASK120067 (limertinib) is an oral third-generation EGFR TKI with proprietary rights, approved by NMPA for the treatment of adults with locally advanced or metastatic EGFR T790M-mutated NSCLC.
Product Name : ASK120067
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 16, 2025
Lead Product(s) : Limertinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Innovent Biologics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Limertinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Innovent Biologics
Deal Size : Undisclosed
Deal Type : Collaboration
Innovent And Ask Pharm Collaborate on Limertinib For Lung Cancer Treatment
Details : Under the agreement, Innovent will obtain the exclusive commercialization rights for limertinib, a third-generation EGFR inhibitor for the treatment of lung cancer, in mainland China.
Product Name : ASK120067
Product Type : Small molecule
Upfront Cash : Undisclosed
October 07, 2024
Lead Product(s) : Limertinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Innovent Biologics
Deal Size : Undisclosed
Deal Type : Collaboration
Reset All
